Tiziana Life Sciences Plc (TLSA)

2.78
0.13 4.32
NASDAQ : Health Technology
Prev Close 2.91
Open 2.62
Day Low/High 2.62 / 2.80
52 Wk Low/High 1.67 / 6.08
Volume 1.57K
Avg Volume 9.70K
Exchange NASDAQ
Shares Outstanding 27.29M
Market Cap 73.33M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity With Milciclib Monotherapy In Advanced Sorafenib-refractory Or -intolerant Patients With Unresectable Or Metastatic Hepatocellular Carcinoma

Tiziana Life Sciences Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity With Milciclib Monotherapy In Advanced Sorafenib-refractory Or -intolerant Patients With Unresectable Or Metastatic Hepatocellular Carcinoma

Tiziana Life Sciences plc (NASDAQ: TLSA), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced additional positive Phase 2a clinical data exhibiting...

Tiziana Reports Phase 2a Clinical Data With Milciclib Monotherapy In Sorafenib-refractory Or -intolerant Patients With Unresectable Or Metastatic Hepatocellular Carcinoma

Tiziana Reports Phase 2a Clinical Data With Milciclib Monotherapy In Sorafenib-refractory Or -intolerant Patients With Unresectable Or Metastatic Hepatocellular Carcinoma

  THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014).

Tiziana Life Science Reports Independent Third Party Article In New England Journal Of Medicine On Intravenous Treatment With A Humanized Anti-CD3 MAb Showing Delays In Progression Of Type 1 Diabetes

Tiziana Life Science Reports Independent Third Party Article In New England Journal Of Medicine On Intravenous Treatment With A Humanized Anti-CD3 MAb Showing Delays In Progression Of Type 1 Diabetes

Tiziana Life Sciences plc (Nasdaq: TLSA/ AIM: TILS ("Tiziana" or the "Company"), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, notes that a recently published study...

Newly Published Article Reporting Clinical Activity Of Orally Administered OKT3, A Mouse Anti-CD3 Monoclonal Antibody, In Moderate To Severe Ulcerative Colitis Patients, Supports Tiziana's Oral Monoclonal Antibody Platform

Newly Published Article Reporting Clinical Activity Of Orally Administered OKT3, A Mouse Anti-CD3 Monoclonal Antibody, In Moderate To Severe Ulcerative Colitis Patients, Supports Tiziana's Oral Monoclonal Antibody Platform

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, notes the advance publication of a...

Tiziana Reports Encouraging Interim Clinical Data From An Ongoing Phase 2a Clinical Trial With Milciclib In Patients With Advanced Liver Cancer

Tiziana Reports Encouraging Interim Clinical Data From An Ongoing Phase 2a Clinical Trial With Milciclib In Patients With Advanced Liver Cancer

Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced results from the interim safety review conducted...

Tiziana Completes Patient Enrollment In A Phase 2a Trial To Evaluate Tolerability And Anti-Tumor Activity Of Milciclib In Hepatocellular Carcinoma (HCC)

Tiziana Completes Patient Enrollment In A Phase 2a Trial To Evaluate Tolerability And Anti-Tumor Activity Of Milciclib In Hepatocellular Carcinoma (HCC)

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that patient enrollment in the ongoing Phase 2a...

Tiziana Announces Initiation Of Phase 1 Clinical Trial With Nasal Administration Of Foralumab, A Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 MAb), In Healthy Volunteers

Tiziana Announces Initiation Of Phase 1 Clinical Trial With Nasal Administration Of Foralumab, A Fully Human Anti-Cluster Definition 3 Monoclonal Antibody (anti-CD3 MAb), In Healthy Volunteers

Tiziana Life Sciences plc ("Tiziana" or the "Company") (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, previously announced that it...

Tiziana Announces Closing Of Offering And Resulting Total Voting Rights

Tiziana Announces Closing Of Offering And Resulting Total Voting Rights

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the closing of its...

Tiziana Announces Pricing Of Offering And Warrant Conversion Raising In Aggregate $5.79 Million Of New Equity Capital, Approval To List On The Nasdaq Global Market And Loan Conversion Extinguishing $1.78 Million Of Debt

Tiziana Announces Pricing Of Offering And Warrant Conversion Raising In Aggregate $5.79 Million Of New Equity Capital, Approval To List On The Nasdaq Global Market And Loan Conversion Extinguishing $1.78 Million Of Debt

Tiziana Life Sciences plc (AIM: TILS) (the "Company" or "Tiziana"), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the pricing of its...

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

Why the VIX Is Set to Spike Even Higher

Why the VIX Is Set to Spike Even Higher

Investors are de-risking everywhere, setting the VIX up for a pop above 20.

Dow Reaches Record High

Dow Reaches Record High

Markets closer mostly higher ahead of pricing on the year's most anticipated tech float tonight - Twitter.